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Introduction: Current U.S. cardiology guidelines recommend oral anticoagulation (OAC) to reduce 
stroke risk in selected patients with atrial fibrillation (AF), but no formal AF OAC recommendations 
exist to guide emergency medicine clinicians in the acute care setting. We sought to characterize 
emergency department (ED) OAC prescribing practices after an ED AF diagnosis.
Methods: This retrospective study included index visits for OAC-naive patients ≥18 years old who 
were discharged home from the ED at an urban, academic, tertiary hospital with a primary diagnosis 
of AF from 2012-2014. Five hypothesis-blinded, chart reviewers abstracted data from patient 
problem lists and medical history in the electronic health record to assess stroke (CHA2DS2-VASc) 
and bleeding risk (HAS-BLED). The primary outcome was the provision of an OAC prescription at 
discharge in OAC-naive patients with high stroke risk. Descriptive statistics and multivariable logistic 
regression assessed associations between OAC prescription and patient characteristics. 
Results: We included 138 patient visits in our analysis, of whom 39.9% (n = 55) were low 
stroke risk (CHA2DS2-VASc = 0 in males and 1 in females), 15.9% (n = 22) were intermediate 
risk (CHA2DS2-VASc = 1 in males), and 44.2% (n = 61) were high risk (CHA2DS2-VASc ≥ 2). Of 
patients with high stroke risk and low-to-intermediate bleeding risk (n = 57), 80.7% were not 
prescribed an OAC at discharge. Cardiology consultation and female gender, but not stroke risk 
(CHA2DS2-VASc score), were predictors of an ED provider prescribing an OAC to an OAC-naive 
AF patient at ED discharge. 
Conclusion: The majority of OAC-eligible patients were discharged home without an OAC 
prescription. In OAC-naive patients discharged home from the ED, cardiology consultation and 
female gender were associated with OAC prescription. Our findings suggest that access to expert 
opinion may improve provider comfort with OAC prescribing and highlight the need for improved 
guidelines specific to ED-management of AF. [West J Emerg Med. 2020;21(4)924–934.]
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Population Health Research Capsule
What do we already know about this issue?
Up to one quarter of all new atrial fibrillation (AF) 
diagnoses are made in the emergency department 
(ED), and AF accounts for more than 500,000 
annual ED visits.
What was the research question?
What factors influence emergency physician oral 
anticoagulant (OAC) prescription rates for patients 
with a primary diagnosis of AF at home discharge?
What was the major finding of the study?
The majority of patients were not prescribed an 
OAC. Cardiology consultation and female gender 
were associated with OAC prescription.
How does this improve population health?
ED-specific guidelines and access to expert opinion 
may improve time to OAC prescription for OAC-
naive AF and reduce the associated morbidity and 
mortality.
INTRODUCTION
Atrial fibrillation (AF) is the most common arrhythmia 
presenting to emergency departments (EDs) and accounts 
for more than 500,000 annual ED visits; up to one quarter 
of all new AF diagnoses are made in the ED.1-2 The 
related costs for these patients total more than $26 billion 
annually.3 Importantly, AF has significant associated 
morbidity and mortality,4 with a fivefold increase in an 
individual’s lifetime risk of stroke when compared to a 
non-AF reference population.5-7 Compared to estimates 
from 2010, the prevalence and incidence of AF are both 
expected to double by the year 2030, when over 12 million 
Americans will be affected.8
Although studies show that oral anticoagulation (OAC) 
therapy with traditional agents such as warfarin or non-
vitamin K oral anticoagulants (NOACs) can reduce stroke 
risk by 64% in non-valvular AF, providers hesitate to 
prescribe OACs for reasons that include increased bleeding 
risk.7,9-11 Professional guidelines recommend the use of 
CHA2DS2-VASc, a validated scoring system that stratifies 
patients’ annual stroke risk based on age, gender, and 
comorbid conditions, and HAS-BLED, a complementary 
scoring system that predicts the likelihood of a major 
bleeding event in anticoagulated patients, to determine 
appropriate OAC recommendations.12-15
Multiple studies show a net positive clinical benefit for 
OAC prophylaxis in AF patients with at least one additional 
risk factor for stroke.7,16-22 With rising pressure to decrease 
unnecessary hospitalizations, up to 89% of patients with 
new-onset AF may be discharged from the ED.17 ED 
providers may defer OAC initiation for a patient with new 
AF to an outpatient provider, but more than half of AF 
patients discharged from the ED fail to achieve outpatient 
follow-up within 90 days of hospital discharge.17,19 Thus, 
ED management at discharge may determine the trajectory 
of care and impact clinical outcomes.
The objective of this study was to describe baseline ED 
OAC prescribing rates for eligible OAC-naive AF patients, 
characterize predictors of OAC prescribing, and identify 
variation from established guidelines and risk-stratification 
tools. This information will inform future interventions 
to improve prescribing in the ED and, ultimately, clinical 
outcomes for AF patients.
METHODS
Study Design and Setting
This retrospective study took place at an academic, 
tertiary care hospital ED with an affiliated emergency 
medicine (EM) residency program staffed by 43 board-
certified faculty and EM residency-trained fellows with 
an annual ED volume of 50,000 adult patients. The study 
was approved by the Oregon Health & Science University 
Institutional Review Board.
Selection of Participants
A query of the electronic health record (EHR) identified 
patients ≥ 18 years old who were evaluated in the ED between 
January 1, 2012–December 31, 2014, and given a primary 
diagnosis of AF (International Classification of Disease-9 
code 427.31) and discharged home from the ED. We excluded 
patients who were taking warfarin or a NOAC at the time of 
presentation. Patients taking aspirin at the time of presentation 
were considered OAC-naive, as aspirin is not recommended 
for those at high risk for stroke.15 Only the first eligible visit 
during the study period was included.
Data Collection and Processing
We collected patient data for all qualifying patient 
encounters using the abstraction criteria described by Kaji et 
al.23 Four chart abstractors blinded to the study hypotheses 
performed the chart review. The principal investigator trained 
each abstractor and provided them with standardized data 
collection procedures and definitions. A random sample of 
10 encounters was selected for re-abstraction to determine 
inter-rater reliability. We assessed Fleiss’ kappa and intraclass 
correlation statistics.
Study data were collected and managed using Research 
Electronic Data Capture (REDCap) electronic data capture 
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tools. REDCap is a secure, web-based application designed 
to support data capture for research studies that is endorsed 
for clinical research purposes by institutions including 
Oregon Health & Science University.24 Abstracted data 
included patient demographics, risk factors for stroke/
bleeding,12,15,25 other comorbidities documented within 
one year of the ED encounter, substance use (alcohol, 
tobacco, illicit drug use), current medication use (OACs, 
antiplatelets, diuretics, heart rate-controlling medications), 
and disabilities or trouble with activities of daily living 
documented within the last year. Abstracted data related to 
management in the ED included chief complaint at time of 
presentation, arrhythmia management attempted in the ED, 
provision of OAC/antiplatelet prescription or adjustment 
to antiplatelet, specialty consultations obtained by the 
ED provider and recommendations for anticoagulation, 
reason from provider for management decisions, patient 
disposition, and follow-up international normalized ratio 
(INR) (if applicable). (See Appendix for further details of 
data captured.) 
Outcome Measure 
The primary outcome was the provision of an OAC 
prescription at home discharge in OAC-naive patients with 
AF and a high stroke risk (CHA2DS2-VASc ≥ 2). OACs 
included warfarin and NOACs (factor Xa and thrombin 
inhibitors). Based on investigator consensus, we simplified 
the indications for stroke prophylaxis to those who would 
be most acceptable by ED providers: AF patients with high 
stroke risk by CHA2DS2-VASc
12 (scores ≥ 2) and low bleeding 
risk by HAS-BLED25 (scores 0-2), where AF patients would 
derive the greatest benefit and the least amount of harm from 
an OAC prescription. Although a high HAS-BLED score 
does not preclude the use of OACs, we chose to exclude them 
from the OAC indicated cohort to simplify the analysis to the 
most obvious cohort needing OACs with minimal concerns of 
adverse events for the risk-averse emergency provider. 
Variables
We identified predictor variables to compare patients 
prescribed an OAC upon discharge from the ED to those 
who were not prescribed an OAC. Variables were selected 
based on the reviewed literature and factors thought to 
impact clinical decision making, and included the following: 
calculated CHA2DS2-VASc and HAS-BLED scores stratifed 
into low, intermediate and high risk; health insurance; gender; 
disabilities; cardiology consultation; return to normal sinus 
rhythm at disposition; whether cardioversion was attempted in 
the ED; and first method of rate or rhythm control attempted. 
All were identified through review of the ED provider and 
consultant notes as well as encounter registration data.
We also compared patients who received a cardiology 
consult in the ED to those who did not in order to 
identify predictors of specialty consultation. Selected 
variables included the following: duration of symptoms; 
health insurance; and comorbidities used to calculate 
the CHA2DS2-VASc score (congestive heart failure, 
hypertension, age, diabetes, gender, stroke/transient 
ischemic attack [TIA], vascular disease). For the patients 
who received a cardiology consultation, we determined 
whether cardiology’s recommendation regarding OAC 
provision agreed with whether the emergency physician 
prescribed an OAC and identified any documented reason 
for discrepancy. 
We documented whether or not the emergency physician 
cited use of a clinical guideline (such as CHA2DS2-VASc or 
HAS-BLED) in his or her clinical decision-making process. 
Similarly, we identified emergency physicians’ reasons for 
lack of OAC prescription in OAC-eligible patients. Lastly, we 
evaluated OAC and NOAC prescribing trends to investigate 
whether physician familiarity with newer drugs influenced 
prescribing of an anticoagulant.
Statistical Analysis
Descriptive statistics were used to summarize age, race, 
ethnicity, insurance, the reason for evaluation, medications 
at the time of the encounter, CHADS2 score, CHA2DS2-
VASc score, HAS-BLED score, and follow-up instructions. 
We used multivariable logistic regression to identify 
factors associated with provision of OAC prescription at 
ED discharge and also to identify factors associated with 
cardiology consultation. Model diagnostics were visually 
inspected for outliers and leverage values. All tests were 
two-sided with a significance level of 0.05. The analysis was 
conducted with SAS 9.4 (Cary, NC, USA).
RESULTS
Characteristics of Study Subjects
During the study period, 317 patients were identified, with 
138 ultimately meeting inclusion criteria (Figure 1). Their 
baseline characteristics are reported in Table 1.
Their mean age was 59 years, 39.1% were female, 
and 39.9% had no history of AF. Overall, 39.9% (n = 55) 
were low risk for stroke (CHA2DS2-VASc = 0 in males 
and 1 in females), 15.9% (n = 22) were intermediate risk 
(CHA2DS2-VASc = 1 in males), and 44.2% (n = 61) were 
high risk (CHA2DS2-VASc≥2)
12 for stroke. About half 
(49.3%) of included patients were taking aspirin at the time 
of presentation.
Main Results
Among the 138 OAC-naive patient-visits, 14.5% (n = 20) 
received a new prescription of warfarin or NOAC at discharge 
for stroke prophylaxis (Table 1). Other medications were not 
included in the analyses, but usage is detailed in Appendix 
Table A1.
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Provision of an Oral Anticoagulant Prescription Stratified By 
OAC-Naive Patients’ CHA2DS2-VASc and HAS-BLED Scores 
OAC prescriptions were provided for 10.9% (n = 6) 
of patients with low stroke risk (CHA2DS2-VASc = 0 in 
males and 1 in females); 9.1% (n = 2) of patients with 
intermediate stroke risk (CHA2DS2-VASc = 1 in males); 
and 19.7% (n = 12) of patients with high stroke risk 
(CHA2DS2-VASc≥2) (Table 2). 
When stratified by HAS-BLED scores, OAC prescriptions 
were provided for 12.4% (n = 10/81) of patients with low 
bleeding risk, 22.6% (n = 7/31) of patients with intermediate 
bleeding risk, and 11.5% (n = 3/26) of patients with high 
bleeding risk. When stroke risk and bleeding risk were 
considered together, we found that patients with a high stroke 
risk and low bleeding risk (n = 13) were prescribed an OAC 
15.4% (n = 2) of the time (Figure 2).   
Among all those prescribed an OAC (any risk) (n = 
20), 10.0% (n = 2) were at intermediate risk and 60.0% 
(n = 12) were at high risk for stroke. Among those at low 
risk of stroke (n = 55), 36.3% (n = 20) received aspirin and 
10.9% (n = 6) received OACs. Of these low-risk patients 
prescribed aspirin, 95.0% (n = 19) were in normal sinus 
rhythm when they were discharged from the ED. Compared 
to the intermediate and high stroke risk patients who 
received an OAC prescription, we found that the low stroke 
risk patients prescribed an OAC were more likely to be 
younger (49.6 years vs 58.7 years), to be female (83% vs 
57% male), to have private or commercial insurance (67% 
138 patients included in 
final analysis
178 patients discharged 
from the ED included
260 index encounters 
for a primary diagnosis 
of AF included
317 patient encounters 
with a primary diagnosis 
of AF identified
Excluded 57 repeat 
patient encounters
Excluded 82 patients 
because patient was 
admitted, transferred, 
died in ED, or had 
unknown disposition
Excluded 40 patients for 
current OAC/NOAC use
Figure 1. Cohort selection of patients with atrial fibrillation.
AF, atrial fibrillation; ED, emergency department; OAC, oral anticoagulant; NOAC, non-vitamin K oral anticoagulants.
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Characteristic (n, %) Overall (n=138,100%) OAC Prescription (n=20,14.5%) No OAC (n=118,85.5%) p-value*
Age (years), mean (SD) 58.7 (17.1) 61.4 (13.8) 58.2 (17.6) 0.69
Female gender 54 (39.1%) 13 (65.0%) 41 (34.7%) 0.01
Race
White 128 (92.8%) 20 (100.0%) 108 (91.5%) 1.00
Black or African American 3 (2.2%) 0 (0.0%) 3 (2.5%)
Asian or Pacific Islander 2 (1.4%) 0 (0.0%) 2 (1.7%)
Other 2 (1.4%) 0 (0.0%) 2 (1.7%)
Not reported 3 (2.2%) 0 (0.0%) 3 (2.5%)
Insurance
Commercial 59 (42.8%) 10 (50.0%) 49 (41.5%) 0.24
Medicare/Medicaid 64 (46.4%) 10 (50.0%) 54 (45.8%)
Other 15 (10.9%) 0 (0.0%) 15 (12.7%)
History of AF 81 (58.7%) 10 (50.0%) 71 (60.2%) 0.29
Symptom onset 
< 6 hours 64 (46.4%) 11 (55.0%) 53 (44.9%) 0.05
6–48 hours 28 (20.3%) 3 (15.0%) 25 (21.2%)
> 48 hours 10 (7.2%) 4 (20.0%) 6 (5.1%)
Unknown 36 (26.1%) 2 (10.0%) 34 (28.8%)
Heart rate on arrival, mean (SD) 118 (31.5) 112 (30.3) 119 (31.7)
Rate-controlling medication PTA 63 (45.7%) 12 (60.0%) 51 (43.2%) 0.16
On aspirin prior to presentation 68 (49.3%) 12 (60.0%) 56 (47.5%) 0.30
CHA2DS2-VASc group
†
Low stroke risk 55 (39.9%) 6 (30.0%) 49 (41.5%) 0.30
Intermediate stroke risk 22 (15.9%) 2 (10.0%) 20 (16.9%)
High stroke risk 61 (44.2%) 12 (60.0%) 49 (41.5%)
HAS-BLED group§
Low bleeding risk 81 (58.7%) 10 (50.0%) 71 (60.2%) 0.42
Intermediate bleeding risk 31 (22.5%) 7 (35.0%) 24 (20.3%)
High bleeding risk 26 (18.8%) 3 (15.0%) 23 (19.5%)
Number of methods of control attempted 
0 57 (41.3%) 10 (50.0%) 47 (39.8%) 0.19
1 52 (37.7%) 4 (20.0%) 48 (40.7%)
2 21 (15.2%) 4 (20.0%) 17 (14.4%)
3 6 (4.3%) 1 (5.0%) 5 (4.2%)
4 2 (1.4%) 1 (5.0%) 1 (0.8%)
First method of control
Rhythm 16 (11.6%) 1 (5.0%) 15 (12.7%) 0.52
Rate 65 (47.1%) 9 (45.0%) 56 (47.5%)
None 57 (41.3%) 10 (50.0%) 47 (39.8%)
Cardioversion attempted 18 (13.0%) 4 (20.0%) 14 (11.9%) 0.30
*t-tests for continuous data, chi-square tests for categorical data, and Fisher’s exact tests for sparse categorical data.
†CHA2DS2-VASc (congestive heart failure, hypertension, age≥75, diabetes mellitus, prior stroke or transient ischemic attack, gender, age 
65-74 years, and vascular disease). 0 in males, 1 in females = low risk for stroke, 1 in males = intermediate risk, and ≥ 2 high risk. 
§HAS-BLED (hypertension, abnormal renal function or liver function, stroke, bleeding, labile international normalized ratio [excluded as all 
patients not on warfarin prior to inclusion], elderly >85 years old, and drugs and alcohol): 0 = low risk, 1 to 2 = moderate risk, >2 = high risk.
OAC, oral anticoagulant; AF, atrial fibrillation; SD, standard deviation; PTA, prior to arrival.
Table 1. Patient characteristics and calculated stroke and bleeding risk scores for 138 OAC-naive atrial fibrillation patients who were 
discharged home from the ED.
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CHA2DS2-VASc score
† HAS-BLED score§ OAC Prescription
Yes (n=20) No (n=118) Total (n=138)
Low stroke risk
Low bleeding risk 6 (11.1%) 48 (88.9%) 54 (100%)
Intermediate bleeding risk 0 (0%) 1 (100%) 1 (100%)
High bleeding risk 0 (0%) 0 (0%) 0 (0%)
Total 6 49 55
Intermediate stroke risk
Low bleeding risk 2 (14.3%) 12 (85.7%) 14 (100%)
Intermediate bleeding risk 0 (0%) 5 (100%) 5 (100%)
High bleeding risk 0 (0%) 3 (100%) 3 (100%)
Total 2 20 22
High stroke risk
Low bleeding risk 2 (15.4%) 11 (84.6%) 13 (100%)
Intermediate bleeding risk 7 (28.0%) 18 (72.0%) 25 (100%)
High bleeding risk 3 (13.0%) 20 (87.0%) 23 (100%)
Total 12 49 61
Table 2. Provision of OAC prescription by CHA2DS2-VASc and HAS-BLED score.
†CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75, diabetes mellitus, prior stroke or transient ischemic attack, gender, age 
65-74 years, and vascular disease). 0 in males, 1 in females = low risk for stroke, 1 in males = intermediate risk, and ≥ 2 high risk. 
§HAS-BLED (hypertension, abnormal renal function or liver function, stroke, bleeding, labile international normalized ratio [excluded as all 
patients not on warfarin prior to inclusion], elderly >85 years old, and drugs and alcohol): 0 = low risk, 1 to 2 = moderate risk, >2 = high risk.
OAC, oral anticoagulant; AF, atrial fibrillation.
vs 43%), to present with a higher heart rate on arrival (137 
vs 112), and have a shorter duration of symptoms, to have 
multiple methods of control attempted, to have cardioversion 
attempted (50% vs 7%), and were less likely to be on aspirin 
at the time of presentation (66.7% vs 33.3%).
Predictors of OAC Prescription 
Multivariable logistic regression showed that cardiology 
consultation and female gender were significant predictors 
of prescribing (Table 3). Females had 2.9 (95% confidence 
interval [CI], 1.0-8.5) times the odds of receiving an OAC 
prescription as compared to males, and patients with a 
cardiology consult had 12.5 (95% CI, 1.5-100.5) times the 
odds of receving an OAC prescription as compared to patients 
without a cardiology consult.
Predictors of Cardiology Consultation 
Cardiology was consulted in 64.5% of all cases. We 
identified hypertension as a significant predictor of cardiology 
consultation after controlling for duration of symptoms, 
insurance status, and comorbidities associated with CHA2DS2-
VASc score calculation (Appendix Table A2). Patients with a 
diagnosis of hypertension had 2.7 (95% CI, 1.0-7.2) times the 
odds of having a cardiology consult compared with patients 
without hypertension.
Cardiologists’ Recommendations for Oral Anticoagulant 
Prescription
For the 89 patients who received a cardiology 
consultation, we examined whether cardiology’s 
recommendation regarding OAC provision agreed with 
whether the ED provider prescribed an OAC. Cardiology 
recommended an OAC prescription for 10 (11.2%) patients, 
recommended against an OAC prescription for 40 (45.0%) 
patients, or opted to discuss OAC management at a later 
time for 19 (21.3%) patients (Appendix Table A3). Their 
recommendation was recorded as “unknown” for 20 (22.5%) 
patients. Other recommendations made by cardiology 
regarding patient management are specified in the appendix 
(Appendix Table A3).
Agreement Between Cardiologists’ Recommendation for 
OAC And ED Provider Prescribing Patterns
For the 89 patients who received a cardiology 
consultation (36 of whom [40.5%] were high stroke risk), 
there were 12 cases in which cardiology’s recommendation 
was not congruent with the emergency physician’s decision 
(Appendix Table A4). 
Cardiology recommended an OAC prescription for 10 of 
the 89 patients (11.2%), of whom seven were not prescribed an 
OAC. Cardiology did not recommend an OAC be prescribed 
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OAC-naive patients, n=138
Low stroke risk, n=55
Intermediate stroke risk, n=22
High stroke risk, n=61
Low bleed risk, n=81
Intermediate bleed risk, n=31
High bleed risk, n=26
No OAC prescribed, n=118
OAC prescribed, n=20
Figure 2. Patients who met exclusion criteria were stratified into low, intermediate, and high stroke risk by CHA2DS2-VASc score. They 
were then further stratified into low, intermediate, and high bleed risk by HAS-BLED scores. Next, they were stratified by prescription of 
oral anticoagulant (OAC) or not.
to 40 patients, although five (12.5%) of these patients were 
prescribed an OAC by the emergency physician. We attempted 
to identify reasons for these discrepancies within the patients’ 
charts and identified one instance in which the ED provider 
opted against the recommended OAC prescription due to the 
patient’s low stroke risk, and another in which the ED provider 
prescribed an OAC after citing the patient’s high CHADS2 score 
(Appendix Table A1). Interestingly, patients who did not receive 
an OAC prescription despite cardiology’s recommendations 
were more likely to have a high HAS-BLED score (2/7 patients 
vs 0/5 patients who received an OAC prescription despite 
cardiology’s recommendation). 
Guidelines Cited by Provider
Of the 138 patient visits included, ED providers cited 
use of a clinical guideline such as CHA2DS2-VASc or HAS-
BLED in AF management in 20.3% (n = 28) of visits. Use 
of a guideline was cited in 20.0% (n = 4) of visits where the 
patient was given an OAC prescription, and in 31.2% (n = 
24) of visits where the patient was not prescribed an OAC or 
antiplatelet. Of all guidelines cited, CHADS2 was the most 
cited guideline, both for or against an OAC prescription. 
All patient visits were reviewed for evidence of reasons for/
against OAC prescription other than use of a guideline. 
Identified Reasons for not Prescribing Oral 
Anticoagulant
We identified one visit in which the provider referenced 
the patient’s inability to follow up as an outpatient as a 
reason to support OAC prescription in the ED. Reasons 
against OAC prescription included low stroke risk (n=17), 
advanced age (n=4), lack of primary care physician 
management and/or follow-up (n=4), and “other” reasons 
(n=21). In patients perceived to be low stroke risk by the 
provider, 64.7% (11/17) were classified as low stroke risk 
by CHA2DS2-VASc. The most common “other” reason cited 
was that the patient was already taking aspirin (n=7). 
Oral Anticoagulant Prescribing Patterns
To evaluate changes in OAC prescribing patterns over 
time, we compared the types of OACs prescribed stratified 
by year in which the ED visit occurred (Appendix Table A5). 
There was no variation in warfarin vs NOAC prescriptions 
provided throughout the study period. 
DISCUSSION
In this study, we found that less than a quarter (15.3%) 
of OAC-naive AF patients at high risk for stroke and low 
risk for bleeding received a new prescription of warfarin 
or NOAC for stroke prophylaxis at the time of ED home 
discharge. This is consistent with findings from a previous 
study.26 Reasons for underutilization of OACs by emergency 
physicians for AF management are likely multifactorial.27-30 
A recent qualitative study by our group found that physicians 
were uncomfortable with prescribing and had a sense of 
futility in prescribing due to concerns that included low 
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Characteristic OR (95% CI) P-value
Gender, Female 2.9 (1.0-8.5) 0.05
CHA2DS2-VASc stratification
High risk 1.9 (0.7-5.7) 0.21
Low/intermediate risk referent
Cardiology consultation 12.5 (1.5-100.5) < 0.01
Table 3.  Factors associated with the provision of oral anticoagulant 
prescription at ED home discharge to 67 (48.2%) of 138 OAC-naive 
AF patients.
Significant values are bolded.
OR, odds ratio; CI, confidence interval; AF, atrial fibrillation.
adherence rates by patients prescribed anticoagulation and 
bleeding risks associated with anticoagulation,31 which are 
further magnified by an emergency physician’s inability to 
follow up with patients. 
A longitudinal cohort study of United States and 
Canadian patients with new-onset AF found that use of 
warfarin decreased from 65% at study enrollment to 44% 
30 months later.29  However, Atzema et al demonstrated 
that patients who received a prescription for warfarin in the 
ED had a higher frequency of long-term warfarin use than 
patients who were referred to another provider for OAC 
management.32 This suggests that there is longitudinal value 
in the initiation of a prescription associated with a significant 
event—an acute care encounter—and that more resources 
should be directed toward the initial acquisition of the 
medication for the patient. One potential solution by Barrett 
et al is the “provision of a protective tail of stroke prevention 
for a limited duration until they can follow up.”33
Interestingly, 10.9% (n = 6/55) of patients were over-
prescribed OACs when they had a low stroke risk. This may 
be driven in part by the increased frequency of cardioversion 
attempted in this group (50% vs 7%), as anticoagulation is 
often continued for four weeks after electrical cardioversion 
and recommended by the American Heart Assocation.15 We 
also found that these patients were more likely to be younger, 
female, and have private or commercial insurance. However, 
these findings contradict those from a study of the Practice 
Innovation and Clinical Excellence (PINNACLE) Registry, 
which found that older age, male gender, and Medicare 
insurance were associated with increased likelihood of OAC 
prescription among AF patients with a CHA2DS2-VASc score 
of 0.34 The reason for this discrepancy is unclear, although 
our small sample size of six patients limits our ability to 
draw a statistically meaningful conclusion.
We found that cardiology consultation was a predictor 
of whether or not OAC-naive patients were prescribed 
an OAC on home discharge. These findings are in 
accordance with recently-published data from the non-
oral vitamin K inhibitor era.35 Similarly, the TREAT-AF 
study found significant, specialty-dependent differences in 
anticoagulation use, with cardiologists being more likely 
to prescribe OACs than primary care physicians.36 This is 
likely due to provider comfort and familiarity with OAC 
prescribing. Additionally, having a cardiology consult may 
overcome barriers to outpatient follow-up as it directly 
connects the patient with a follow-up provider. Concern 
regarding lack of follow-up has been previously identified 
as a barrier to OAC prescription in the ED,31 and a lack 
of follow-up after ED discharge has been associated with 
increased mortality in AF patients.26,30,37  
However, we also found that ED providers did not 
always abide by cardiology’s recommendations regarding 
OAC management, as management in the ED was 
incongruent with cardiology’s recommendations for 12 of 
89 (13.5%) patients who received a cardiology consult. 
Although ED providers did not provide reasons for these 
discrepancies, patients who did not receive an OAC 
prescription, despite cardiology’s recommendations, were 
more likely to have a high-risk HAS-BLED score. While 
our simplified outcome maximized benefit and minimized 
harm (high stroke risk and low bleeding risk), we must 
acknowledge that a high bleeding-risk score does not 
preclude patients from being on OACs, and in fact, may still 
be indicated as the two risk scores share many features.
It is important to note that cardiology consults occurred 
in roughly two-thirds of encounters in our study population. 
This is higher than cardiology consults obtained in non-
academic settings, with a recent study of Northern California 
Kaiser Permanente AF patients showing that cardiology was 
consulted 37.5% of the time.35 This reinforces the importance 
of improving emergency physician comfort with OAC 
prescribing independently of cardiology consultation. 
Despite the fact that CHA2DS2-VASc and HAS-BLED 
risk scores are well-validated tools in the AF population, 
we found that they did not influence OAC prescribing. 
This reflects findings from a previous study that found 
only a modest correlation between CHADS2 score and 
warfarin prescribing in an elderly AF population.38 This 
may be because emergency physicians underutilize the 
tools (potentially due to unawareness of the guidelines), 
or because they overvalue the risk of adverse events (eg, 
major bleeding events) when considering OAC initiation. 
However, a recent multicenter prospective cohort study in 
Spain showed that anticoagulation initiated in the ED for 
AF patients with high stroke risk was not associated with an 
increase in major bleeding event by one year and was in fact 
associated with a decrease in mortality.39 
We reviewed the reasons documented by physicians 
either for or against OAC prescription and found that use of 
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a guideline was cited in only 20.3% of visits. This finding 
may suggest physicians’ unfamiliarity with risk-stratification 
tools not specifically intended for ED populations. A 
recent study reflected similar results, finding that among 
1200 patients hospitalized at a community teaching 
institution with documented AF, only 14% had a CHA2DS2-
VASc score documented in their charts.13,40 Those with a 
documented score were significantly more likely to have 
appropriate anticoagulation therapy, regardless of rate or 
rhythm control.13,40  Expanded efforts to educate emergency 
physicians on the use of these clinical decision-making tools 
may improve comfort with prescribing OACs, and thus 
improve time to appropriate anticoagulation. 
This study contributes to the literature base describing 
NOAC-era ED prescribing practices for AF in OAC-naive 
patients.26,35  ED studies were limited to the use of warfarin 
until recently, but also show inappropriately low rates of 
OAC provision at ED discharge, ranging from less than 
one-quarter to nearly one-half of patients deemed eligible 
by calculation of stroke and bleeding risks.26,32,35,41 The 
number of patients prescribed NOACs is rapidly increasing, 
and it is critical to understand how this can inform clinical 
recommendations specific to the ED setting.24,42 Because our 
study took place over two years, we were able to evaluate 
changes in the rate of NOAC prescriptions over time and 
did not observe a significant change (Appendix Table A5). 
This is supported by a recent study showing the use of 
NOACs gradually increased over a three-year span (2012-
2014); however, the use of warfarin was still 10-50 times 
more common than dabigatran, rivaroxaban, and apixaban 
as of 2015.43 In part, this may be due to challenges of 
prescribing NOACs from the ED as they often require prior 
authorization from a patient’s insurance.
Our work has again demonstrated an ED prescribing 
practice gap for anticoagulants in patients with a primary 
diagnosis of AF.26,32,35,41 However, it also showed that ED 
providers initiate OAC prescribing that may be incongruent 
with a cardiology consultation. Of note, while cardiology 
consultations influenced prescribing, they did not always 
correlate with the ED provider’s decision at the time of 
discharge. The inconsistencies in OAC prescribing are likely 
in part due to the lack of consensus guidelines for acute, ED-
specific AF management, and has been previously noted in a 
qualitative study interviewing providers who were concerned 
about the lack of ED-specific guidelines as current guidelines 
use data from outpatient, chronic care populations.14,31,44 With 
no formal ED recommendations in place, it is not surprising that 
more than half of patients with AF and high stroke risk do not 
receive an OAC prescription at the time of home discharge.41 
A lack of guideline utilization by providers may 
include (1) wariness of using scoring tools that are not 
specifically validated in ED populations; (2) hesitancy to 
start aggressive anticoagulation therapy without definitive 
follow-up; (3) over-reliance on cardiology consultants; and 
(4) lack of education regarding clinical decision-making 
tools (CHA2DS2-VASc and HAS-BLED), as well as other 
reasons.31 There is an opportunity to engage emergency 
physicians to validate existing clinical algorithms for 
AF management in ED populations. Systems-specific 
interventions and electronic clinical decision support could 
include improved methods for establishing outpatient follow-
up after ED evaluation. These are several of many ways 
emergency clinicians can be empowered to contribute to 
multidisciplinary efforts to prevent strokes in patients with 
high-risk AF.45
LIMITATIONS
Patients were included only if they had a primary ED 
diagnosis of AF, and therefore the conclusions from this 
study may not be applicable to patients with a different 
primary diagnosis accompanied by AF (e.g., a patient with 
pneumonia noted to have incidental AF). Patients with 
related diagnoses such as atrial flutter were not included. The 
degree of valvular disease was not abstracted. In addition, we 
included only patients who were discharged home from the 
ED. As a result, our patient population may have reflected 
patients with lower stroke and/or bleeding risk (determined 
by CHADS2, CHA2DS2-VASc, and HAS-BLED tools), fewer 
co-morbidities, and a more favorable disposition status.
This retrospective study is limited to one academic, 
tertiary care, urban hospital and our results may be 
influenced by regional and/or institution-specific practice 
patterns, and our analysis is limited by what was available 
in the EHR. Prospective validation and external validation at 
other EDs is needed. 
CONCLUSION
Our study suggests that current risk stratification tools 
for AF management are ineffectively used in the ED. 
Cardiology consultation and female sex were the only 
variables associated with OAC prescription at discharge. 
This may be explained by ED providers’ unfamiliarity 
with risk-stratification tools, lack of comfort with OAC 
prescribing, or inability to facilitate patient follow-up. Clear 
guidelines for ED providers are critical in this high-risk and 
undertreated population. Possible solutions include new 
algorithms, expanded educational dissemination of existing 
guidelines, or collaborating with cardiology departments 
to create protocols for initiation of anticoagulation by ED 
providers coupled with automatic and timely outpatient 
follow-up for longitudinal management.
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